Table 1. The clinic-pathological significance of PLK1 in cervical cancer.
| Clinico-pathological variables | High PLK1 expression | Low PLK1 expression | χ2 | P | ||
|---|---|---|---|---|---|---|
| Number of cases % | Number of cases % | |||||
| Tissue type | 11.108 | 0.001 | ||||
| Cervical cancer | 179 | 61.7 | 111 | 38.3 | ||
| Non-cancer | 2 | 15.4 | 11 | 84.6 | ||
| Subtype | ||||||
| CESC | 145 | 64.2% | 81 | 35.8% | 2.889* | 0.089 |
| Cervical adenocarcinoma | 33 | 52.4% | 30 | 47.6% | ||
| Malignant mullerian mixed tumor | 1 | 100% | 0 | 0% | ||
| Age | 0.656 | 0.418 | ||||
| ≤44 | 88 | 59.5 | 60 | 40.5 | ||
| >44 | 91 | 64.1 | 51 | 35.9 | ||
| FIGO stage | 1.862 | 0.172 | ||||
| I+II | 99 | 66.4 | 50 | 33.6 | ||
| III | 67 | 58.3 | 48 | 41.7 | ||
| T stage | 1.89 | 0.169 | ||||
| T1+T2 | 175 | 61.2 | 111 | 38.8 | ||
| T3+T4 | 3 | 100.0 | 0 | 0.0 | ||
| N stage | 29.859 | <0.001 | ||||
| N0 | 112 | 52.3 | 102 | 47.7 | ||
| N1-2 | 66 | 88.0 | 9 | 12.0 | ||
Notes.
FIGO: Federation of Gynecology and Obstetrics.
Chi-square test was used for comparing PLK1 protein expression in different clinical parameter groups.
*
Comparison of PLK1 protein expression in different subtypes of cervical cancer was made between CESC and cervical adenocarcinoma.